Overview

Corporate Profile

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that provide unique and meaningful advantages to people with renal disease and their healthcare providers. In September 2014, the U.S. Food and Drug Administration approved Keryx’s first medicine. Patients have been and continue to be at the center of our 17-year corporate history.

Keryx established its corporate headquarters in Boston to support the U.S. launch of its first medicine. Joining Boston’s pioneering biotech community has given us the opportunity to bring together a seasoned talent pool of innovative minds and resources that will allow us to continue toward our goal of building a leading renal company. We are a rapidly growing company, with approximately 185 full-time employees across Boston, New York, and our field team.

Stock Quote

KERX (Common)
ExchangeNASDAQ (US Dollar)
Price$7.42
Change (%)0.00 (0.00%)
Volume509,477
Data as of 07/25/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Featured Report

View the 2015 Annual Report on Form 10K  - PDF View the 2015 Annual Report on Form 10K
Get help downloading or viewing the above file types

Recent News

DateTitle 
06/27/16Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and StrategyPrinter Friendly Version
06/21/16Keryx Biopharmaceuticals Appoints Two New Board Members Printer Friendly Version
06/14/16Keryx Biopharmaceuticals to Present at JMP’s Life Science Conference on Tuesday, June 21Printer Friendly Version
04/28/16Keryx Biopharmaceuticals Announces First Quarter 2016 Financial ResultsPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.